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Sickle cell disease (SCD) does not occur in the indigenous German population, but with the increasing number of immigrants
from countries at high risk for hemoglobinopathies, the question emerges whether or not a newborn screening program (NBS) for
SCD disease should be initiated in Germany anyhow. We have recently shown that in Berlin, a city with a very large immigrant
population, the incidence of SCD is considerable, but our findings are insufficient to make a decision for the country as a whole.
In this paper we will show that a large body of epidemiological data can be generated in a relatively short period of time, with a
very high degree of precision and at relatively little expense—a result that might motivate other working groups to start such a
pilot project locally. We examined previously collected dried blood cards that were up to six months old, using high performance
liquid chromatography (HPLC) as first method and capillary electrophoresis (CE) as secondmethod. A single, part-time laboratory
technician processed 38,220 samples in a period of 162 working days.The total costs per sample including all incidentals (as well as
labor costs) were EUR 1.44.
1. Introduction
1.1. Sickle Cell Disease. SCD is one of the most common
monogenetic diseases worldwide. Although it is most preva-
lent in Africa, in parts of the easternMediterranean and Asia,
as a result of migration, the prevalence is also continuously
increasing in central and northern Europe. SCD comprises a
group of autosomal recessive 𝛽-hemoglobinopathies whose
common feature is the occurrence of the pathognomonic
hemoglobin variant hemoglobin S (HbS). Its genetic correlate
is the mutation HBB:c20A>T which is found in all patients
and which can occur homozygously or as compound het-
erozygous state in combinationwith a number of othermuta-
tions (e.g., HbC or 𝛽-thalassemia). In comparison with adult
hemoglobin A (HbA) there is an amino acid substitution
in the HbS molecule, with valine instead of glutamic acid
in position 6 of the 𝛽-globin polypeptide chain. If the HbS
content in an erythrocyte exceeds a critical concentration this
leads under certain conditions to polymerization of deoxy-
genated HbS molecules, the central pathophysiological event
of SCD. Through a complex process this results in acute and
chronic hemolysis as well as recurrent vasoocclusive events
causing pain, ischemia-reperfusion injury, and finally chronic
organ damage [1].
1.2. Newborn Screening for Sickle Cell Disease. Numerous
studies provide clear evidence that life-threatening early com-
plications of SCD (e.g., sepsis, splenic sequestration crisis,
etc.) can be largely avoided if the diagnosis is made early, that
is, if possible in the first three to six months of life. Simple
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but very effective prophylactic measures (e.g., vaccination,
penicillin prophylaxis, etc.) can then be initiated sufficiently
early. This can considerably reduce morbidity and mortality
[2–10]. In numerous countries SCD is therefore an established
component of national NBS programs. In many other coun-
tries in which there are no national NBS programs there are
at least some regional projects and pilot studies [11–30].
The physicochemical properties of HbS differ from those
of the normal HbA.This phenomenon is utilized for diagno-
sis. All physiological hemoglobins as well as all hemoglobin
variants show characteristic but not unambiguous migration
patterns in all established separation methods. As in each
method there are hemoglobins with the same or comparable
migration characteristics it is not possible to establish conclu-
sively which hemoglobin is present in the concrete case. This
means that the results of at least two different methods have
to be combined in order to be able to identify the hemoglobin
present with sufficient certainty [31–34].This rule also applies
to NBS for SCD to avoid false-positive results. The methods
most commonly used in NBS for SCD for separation of the
hemoglobins in dried blood specimens are HPLC, isoelectric
focusing (IEF), and CE [32, 35–37].
1.3.TheGermanNewborn Screening Program. InGermany all
newborns are entitled by law to take part in a national (so-
called extended) NBS program [38]. However, participation
is voluntary. The extended NBS comprises 14 congenital
endocrine and metabolic disorders. It does not include SCD.
In addition all newborns are screened for hearing defects.The
list of disorders screened for in the German NBS program
is laid down by the Federal Joint Committee (“Gemeinsamer
Bundesausschuss,” G-BA).TheG-BA issues the guidelines for
the statutory health insurance funds (GKV) covering more
than 70 million insured persons in Germany. It specifies
which services in medical care are reimbursed by the GKV. If
a new disease is to be included in the extended NBS program
it must meet the Wilson-Jungner criteria as modified by
Andermann et al. [39, 40] to fit the special conditions of the
German health system. In particular there must be sufficient
epidemiological data and it must have been demonstrated
that early detection of the disease in question is associated
with a medical and/or economic benefit.
1.4. Sickle Cell Disease in Germany. In Germany there are
practically no epidemiological data on the incidence and
prevalence of SCD. SCD has therefore not been perceived as a
significant problem in the German healthcare system to date.
In Berlin, a city presumed to have a high incidence, we per-
formed a pilot project hitherto unique in Germany in which
all newborns born between 1 September 2011 and 30 Novem-
ber 2012 who had given blood samples in the context of
the extended NBS program were retrospectively additionally
tested for SCD [41]. The age of the specimens presented a
methodological challenge. However, two earlier publications
have shown that storage for at least six weeks at room
temperature or 13 months at −20∘C was possible [42, 43].
In addition to generation of epidemiological data, a further
goal of the project was therefore to investigate whether
the dried blood specimens can be stored for longer than
six weeks at room temperature and how they need to be
processed after longer storage times in order to obtain reliable
measurements. These are important parameters for planning
similar epidemiological pilot studies.
In this paper we report on the technical aspects of our
study and we discuss in more detail the special legal situation
in Germany.
2. Methods
2.1. Ethics and Consent. The ethics committee of the Charite´
university hospital approved the study on 28 September 2011
(reference number EA2/088/11). The parents of all newborns
investigated gave their written informed consent to reanalysis
of blood in advance of sampling.
2.2. Study Design and Population. The present study is a
retrospective cross-sectional investigation of an unselected
cohort of newborns. All children born in Berlin between
1 September 2011 and 30 November 2012 were considered
eligible for this project provided they took part in the
extended NBS program. Berlin is the capital of Germany and,
after London, the secondmost populated city in the European
Union. On December 31, 2010, Berlin had a population
of 3,460,725 of which 864,065 (24.97%) had a migration
background. Of those, at least one half immigrated from
countries with a high prevalence of hemoglobinopathies [44].
Altogether 39,249 babies were born in the study period.
Of these, 95 parents or guardians did not give their consent to
participation in the extended NBS. A further 422 babies were
not included in the study because the parents or guardians did
not consent to storage of their children’s specimens beyond
the time necessary for the regular screening. In 126 cases
no consent was given to use of the specimens in a scientific
project and in 386 cases there was too little material available
to test additionally for SCD after the regular screening, so that
in the end 38,220 samples could be tested.
2.3. Target Conditions. The primary target conditions of this
study included SCD-S/S, SCD-S/C, SCD-S/DPunjab, SCD-S/E,
SCD-S/Lepore, SCD-S/OArab, SCD-S/𝛽-thalassemia, SCD-
S/𝛿𝛽-thalassemia, and SCD-S/HPFH (hereditary persistence
of fetal hemoglobin). Secondary target conditions were HbS
heterozygosity, severe thalassemia, and all hemoglobin vari-
ants other than HbS in hetero- or homozygous form.
2.4. Blood Sampling and Logistics. The screening specimens
were normally collected from the newborns in the maternity
clinic or at home between the 36th and 72nd hours of
life and sent to the Berlin NBS laboratory the same day
in the form of dried blood spot cards (Ahlstrom 226, ID
Biological Systems,Greenville, SC,USA).TheBerlinNBS lab-
oratory (Laboratory 1) is one of 11 NBS laboratories in
Germany (http://www.screening-dgns.de/screening-3.php),
which analyze specimens in the context of the extended NBS
program, and is the only NBS laboratory in Berlin.
In newborns with a gestational age of less than 32 weeks
the initial screening was followed by a second screening at
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Figure 1: Decision tree for handling samples of the babies born in the study period (𝑛 = 39,249). Samples were excluded if there was no
consent for screening (𝑛 = 95), no consent to store the sample (𝑛 = 422), and no consent to use the sample in a scientific project (𝑛 = 126),
too little material (𝑛 = 386) or a low AUC on the HPLC machine (𝑛 = 4,236). Please note if any hemoglobin variant other than HbS was
detected by means of HPLC, this result was also confirmed by CE.
a corrected age of 32 gestational weeks. Further reasons for
repeat screening were performance of blood transfusions or
corticosteroid or dopamine therapy before collection of the
specimens for the first screening [45]. In patients screened
more than once the test for SCD was performed with the last
specimen obtained.
After completion of the regular screening in the context
of the extended NBS program the specimens were stored
at room temperature in the NBS laboratory. They were for-
warded after 42 to 171 days for examination in the context of
our project.
2.5. Measuring Methods. All specimens were first examined
by HPLC. Specimens with HPLC profiles consistent with
SCD, sickle cell trait, 𝛽-thalassemia, or variant hemoglobins
other than HbS were subsequently analyzed by CE as a
confirmatory method [41] (Figure 1).
2.6. High Performance Liquid Chromatography (HPLC). The
HPLC was performed on a VARIANT nbs Newborn Screen-
ing System (Bio-Rad Laboratories, Munich, Germany) using
the VARIANT nbs Sickle Cell Program. Unless expressly
stated otherwise we followed the manufacturer’s recom-
mendations. The columns and all reagents such as buffers,
primers, and retention timemarkerswere purchased from the
manufacturer.
A disk with a diameter of 1/8󸀠󸀠 (3.2mm) was punched out
of the dried blood card and placed in a well of a 96-well plate.
240𝜇L distilled water was added per punched-out disk and
the sample incubated for 21 hours (overnight) at 4–6∘C. The
eluate was then centrifuged for 10minutes at 1200 g to remove
the solid elements (disk, blood clots, cellulose remains, etc.)
remaining in the sample.The pellet was left in the sample and
the supernatant measured with evaporation protection.
The VARIANT nbs Newborn Screening System has a
dual-wavelength detector, which measures the absorbance
of the sample components at 415 nm. Background noise is
reduced by additionally measuring each sample at 690 nm.
The absorbance data are then transferred from the detector
to a connected PC and converted with the software GDM
3.0 (Bio-Rad Laboratories, Munich, Germany) to a real time
chromatogram in which the measured voltages (𝑦-axis) are
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plotted against the time (𝑥-axis). The software analyzes the
chromatograms fully automatically using the principle of
valley-to-valley integration.
In addition all chromatograms were visually inspected.
Water blanks served as negative controls and were
included in every run. As controls of the preanalytical process
and the automated integration and quantitation of the peaks
we used eluates from dried blood spot cards from HbS and
HbC carriers and retention time markers provided by the
manufacturer. Interrun coefficients of variation (CV) were
determined.
2.7. Capillary Electrophoresis (CE). For the CE a disk 3.8mm
in diameter was punched out of the dried blood spot card and
placed in a well of an 8-well strip tube. After adding 50 𝜇L
distilled water the sample was incubated in the CAPILLARYS
humidity chamber at 4–6∘C for not less than two hours
and not more than 72 hours. Then 0.6mL of hemolysing
solution was added. Measurement of the hemolysate was
then performed on a CAPILLARYS 2 CE system. In each
run controls with hemoglobins A, F, S, and C provided by
the manufacturer were measured. Data acquisition, manage-
ment, and analysis were conducted with the PHORESIS 6.51
software. All material for the CE was purchased from Sebia,
Fulda, Germany.
2.8. Handling of Results. If both HPLC and CE analyses
of a baby’s blood were indicative of SCD, the family was
contacted and referred to our department of pediatric hema-
tology, where the presumed diagnosis was confirmed from a
fresh blood sample by molecular genetic analysis. Telephone
numbers and addresses were extracted from the routine NBS
database. Carrier states were not reported as required by our
local ethics committee.
3. Results
A maximum of four 96-well plates was measured per day
and 455 plates were measured in 180 runs. Six column lots
were used during the entire study. Altogether 38,220 samples
were screened by HPLC, 34,084 of which were subject to
evaluation. 4,236 samples had to be excluded because the
corresponding chromatograms showed a low total AUC.
As expected, the percentage of samples with a low AUC
was positively correlated with sample age (Figure 2). Older
samples showed more degradation of hemoglobin resulting
in more background noise and less analyzable material.
Older samples also contained more filter paper lint, which
interfered with the analysis by causing technical problems
such as pressure increases or detector errors. In one case
we observed a retention time shift. With 74 of our oldest
84 samples (88.1%) we obtained chromatograms with an
AUC > 900,000𝜇Vs, although they had been taken from
dried blood spot cards 171 days previously. The samples thus
fulfilled theminimum criteria for testing which we defined as
“adequate quality.” Nevertheless the proportion of unusable
results increased significantly when the dried blood cards


















Age of samples (days)
Figure 2: Each dot represents themean of an average of 353 samples
(range 24–1090) of the same age. Of the samples that were analyzed
within threemonths after being taken normallymore than 90%were
evaluable.
3.1. Screening-Positive Newborns. Of 34,084 samples
included, 14 samples showed an HPLC pattern consistent
with the diagnosis of SCD. 10 of which were interpreted as
FS; that is, only hemoglobins F and S were assumed to be
present. An FS pattern indicates homozygosity for HbS as
well as compound heterozygosity for HbS and 𝛽-thalassemia
or 𝛿𝛽-thalassemia or HPFH, respectively. In four newborns
we detected an FSC pattern; that is, only hemoglobins F, S,
and C were present in these babies. This is only explainable
by compound heterozygosity for HbS and HbC clinically
resulting in SCD-S/C (Figure 3).
CE was used to corroborate HPLC results. In all 14
cases, CE patterns were consistent with the corresponding
HPLC results. Consequently, these newborns were consid-
ered “screening positive” and appointed to our pediatric
hematology outpatient clinic to finally confirm diagnoses
(Table 1). We did not observe false-positive findings.
3.2. Screening-Negative Newborns. The remaining 34,070
newborns showed hemoglobin patterns without any evi-
dence of any phenotype of SCD and were thus classified as
“screening negative.” Among these we identified a total of 236
newborns who were heterozygous for a hemoglobin variant.
This was HbS in 165 cases, HbE in 27, HbC in 23, and HbD
in 11. In ten further cases there was a variant other than HbS,
E, C, or D. In the cases interpreted as heterozygosity for HbS
the HbS :HbA ratio was <2.0.
Until to date, it has not come to our attention that in
any of these screening-negative babies the diagnosis of SCD
has been made afterwards. However, these children are now
between 14 and 28 months of age and follow-up is not
systematically organized. So it is possible that screening false-
negative subjects, for example, children suffering frommilder
subtypes of SCD like SCD-S/𝛽+ thalassemia, are missed.
3.3. Precision of HPLC. Retention time markers (RTM) were
provided by the manufacturer. RTM are lyophilized controls
containing hemoglobins F, A, E, and S and hemoglobins F, A,



























































































































Figure 3: Representative HPL chromatograms with the presumed hemoglobin patterns FA (a), FAS (b), FS (c), and FSC (d).
D, and C, respectively, to monitor the precise separation of
the aforementioned hemoglobins by the HPLC instrument
[46]. RTM help to detect instabilities in pump pressure or
gradient composition which is an indispensable requirement
for correct analytical performance, because raw data are
processed electronically and the correct interpretation and
integration of peaks appearing in particular time windows
require the full functionality of the hardware.
If the RTM indicated a functional disorder of the HPLC
machine, we repeated the runs that were probably affected.
Table 2 shows our results of several measurements (𝑛 =
130) of the retention time markers in comparison to the
manufacturer’s specifications. Our data show a high precision
of retention times (CV≤ 1.5%).Themaximumdeviation from
mean retention time was ±0.042min for HbS.
Table 3 shows the mean and the range of retention times
of the various hemoglobins detected in the dried blood spot
samples of our study population. The retrospective analysis
of these retention times provides information about the
stability of the HPLC system over the whole study period
with this challenging material. The CV was ≤ 1% for all main
hemoglobins (A, S, E, D, and C).
As many factors during the whole analytical procedure
may affect test results, dried blood samples from five new-
borns, found to be heterozygous for either HbS or HbC,
respectively, were established as additional quality controls.
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Table 1: Detailed information on screening-positive babies.
Patient number (ethnical origin) Screening patterns HPLC/CE Molecular genetic result
# 1 (West African) FSa/FS SCD-S/S
# 2 (West African) F5SaB/FS SCD-S/S
# 3 (Middle East) FSa5B/FS SCD-S/𝛽0 thalassemia
# 4 (West African) FaCS/FSC SCD-S/C
# 5 (Middle East) F4SA/FS SCD-S/S
# 6 (West African) FSCa/FSC SCD-S/C
# 7 (Middle East) FSa5/FS SCD-S/S
# 8 (West African) FSaB/FS SCD-S/S
# 9 (West African) FS4a/FS SCD-S/S
# 10 (West African) FS5aB/FS SCD-S/S
# 11 (West African) FCSa/FSC SCD-S/C
# 12 (West African) FSa2B/FS SCD-S/S
# 13 (West African) FSa2B/FS SCD-S/S
# 14 (West African) FCS1/FSC SCD-S/C
Table 2: High interrun precision of HPLC retention times of retention time markers.




F 0.494 (0.471–0.510) 1.5 0.530 (0.470–0.590)
A 0.792 (0.770–0.804) 0.9 0.800 (0.730–0.870)
E/A2 0.954 (0.919–0.970) 1.0 0.970 (0.930–1.010)
D 1.042 (1.005–1.072) 1.1 1.060 (1.010–1.110)
S 1.158 (1.116–1.183) 1.2 1.190 (1.130–1.250)
C 1.663 (1.634–1.684) 0.6 1.680 (1.610–1.750)
Table 3: High precision of HPLC retention times of hemoglobins derived from dried blood spot samples.
Presumptive hemoglobin Retention times mean (range) [min] CV [%] 𝑛
A 0.800 (0.785–0.816) 0.8 100
E 0.952 (0.936–0.968) 0.8 26
D 1.044 (1.028–1.060) 1.0 11
S 1.154 (1.190–1.130) 0.9 100
C 1.660 (1.647–1.670) 0.4 23
These samples were randomly integrated into several runs
including all steps from pre- to postanalytics to include all
influencing factors. Table 4 shows the results of repeated ana-
lyzes of these quality control samples known to be heterozy-
gous for HbS (A) or HbC (B) on different working days.
3.4. Precision of CE. As quality controls of CE liquid control
samples containing hemoglobins F, A, S, and C were used in
each run on different working days (Table 5).
3.5. Costs. All in all we examined samples from 38,220 new-
borns, 37,970 only by HPLC, 250 additionally by CE, because
the samples showed an abnormal hemoglobin pattern in the
HPLC. For the examination of the entire cohort we incurred
costs of EUR 55,000. A large part of this sum (just under
50%) was labor costs. However, the sum also contains the
costs for instrument hire, for consumables, and so forth.This
translates into a per-sample cost of EUR 1.44 (US$1.97).
4. Discussion
There are practically no epidemiological data to date on the
prevalence and incidence of SCD in Germany [41, 47, 48].
Cautious estimates made so far suggest a figure of about 3000
to 4000 patients in the whole country. These patients are
without exception of immigrant origin [47].
Over a period of more than one year we tested, without
preselection on the basis of ethnic origin, 87% of all children
born in Berlin (34,084 of 39,249) for the presence of SCD
and identified 14 with the disease [41]. The incidence of SCD
(4.11/10,000) amongst the children examined was thus higher
than the incidence of any other endocrine or metabolic
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Table 4: (a) Interrun precision of HPLC determined on two dried blood spot samples from newborns heterozygous for HbS. (b) Interrun
precision of HPLC determined on a dried blood spot sample from a newborn heterozygous for HbC.
(a)
HbF mean [%] CV [%] HbA mean [%] CV [%] HbS mean [%] CV [%] 𝑛
Control 1 37.3 2.9 8.9 5.3 3.6 6.3 11
Control 2 40.1 4.8 1.9 27 1.0 50 8
(b)
HbF mean [%] CV [%] HbA mean [%] CV [%] HbC mean [%] CV [%] 𝑛
Control 3 39.6 5.7 1.7 22 1.3 28 11
Precision was reduced if certain hemoglobin fractions were present in an order close to the detection limit of 1% of the total AUC.
Table 5: Interrun precision of CE determined on liquid control samples provided by the manufacturer.
HbF mean [%] CV [%] HbA mean [%] CV [%] HbS mean [%] CV [%] HbC mean [%] CV [%] 𝑛
Control FASC 18.8 4.8 35.5 2.0 14.5 4.3 5.4 7.7 5
disorder tested for in the context of the German extended
NBS program. SCD should therefore be included in the NBS
at least in Berlin. In order to decidewhether there is a need for
a national NBS program for SCD we now require data from
other regions, particularly from presumed low-prevalence
areas.
The results presented in this paper show that such epi-
demiological data can be generated with investment of
relatively little time and money as the samples do not need
to be examined fresh on a day-to-day basis. Instead, large
numbers of samples can be analyzed retrospectively. It is clear
that the costs per sample (1.44 EUR) in the context of our
pilot study will not be comparable with the expenses in the
context of a national screening program. While the costs for
consumables, and so forth, would probably be a little lower
on account of the substantially higher patient numbers, there
would be considerable additional expenses for administrative
purposes such as quality assurance. Further additional costs
would arise for staff training and for the entire infrastructure,
which has to be made available around the actual testing.
In this study dried blood spot cards up to six months
old provided satisfactory results. However, very old samples
present a particular challenge because cellulose particles,
which come off the dried blood cards together with the blood,
can interfere considerably with the measurement. They are
deposited in the fine capillaries of themeasuring instruments,
clogging them or creating additional, unspecific measuring
signals. The continuously increasing degradation of the
hemoglobin also leads to additional measuring signals, par-
ticularly to increased background noise, as well as reducing
the amount of analyzable material. In the worst case, one
might evenmiss a significant disease due tomisinterpretation
of a peak resembling HbA; for example, a 𝛽-thalassemia
major pattern could be confused with a physiological FA
pattern or homozygosity forHbS could be confusedwith SCT.
Sample preparation is therefore of decisive importance.
Factors, which can influence the sample quality, are as
follows.
(1) The concentration of the hemoglobin in the
hemolysate. This depends on the volume of the
blood sample, thus on the saturation of the filter card
and on the degree of degradation of the hemoglobin.
The latter is essentially dependent on the age and the
storage conditions of the sample. Further important
parameters are the elution volume and elution time.
(2) Instrument performance is influenced significantly by
the condition of the dried blood spot card. This is
in turn also dependent on the sample age and the
storage conditions. In the case of older cards cellulose
particles are removed from the card together with the
blood and can then interfere with the measurement.
Prolonging the elution time increases the hemoglobin
concentration in the hemolysate and also the likelihood of
cellulose particles becoming detached from the filter card.
The elution conditions described in the methods section take
into account both phenomena and represent the necessary
compromise.
The implementation of pilot studies of this kind requires
the availability of a high throughput method. In our expe-
rience, HPLC and CE are equally suitable. The CE electro-
pherograms appeared to us to be easier to interpret than the
HPLC chromatograms because there were fewer unspecific
signals in the former. Whichever method is chosen, it is
crucial that the analytical laboratory has special expertise
with regard to the IT-supported interpretation of the raw
measurements.
Disease screening programs are characterized by the fact
that certain people are examined for the presence of a certain
disease simply because they belong to a certain population.
The subjects are examined or tested regardless of whether
there is any concrete reason to suspect the presence of
8 BioMed Research International
the target disease. The large majority of the subjects screened
are completely healthy. This raises particular ethical, legal,
technical, and economic issues.
The German Genetic Testing Act (GenDG) came into
force on January 2, 2010 and is a constant topic of debate on
account of its very strict regulations [49]. It controls genetic
testing in humans and the use of genetic samples and data.
The GenDG specifies, interalia, that analyses of the products
of nucleic acids (gene product analyses) are also considered
genetic analyses and therefore deemed legally equal to exam-
ination of the number and structure of the chromosomes and
of themolecular structure of DNA and RNA.Thismeans that
hemoglobinopathy testing using protein separation methods
such as HPLC or CE comes under the GenDG.
Theultimate goal of theGenDG is to prevent the potential
dangers and discrimination associated with the examina-
tion of human genetic traits. One of the most important
principles is the right of the individual to informational
self-determination. This right, which enjoys internationally
unique protection in Germany, includes the right to know
and, more important in this context, the right not to know.
Its most important implication is that we are not allowed in
Germany to report sickle cell trait.
The GenDG distinguishes between genetic tests per-
formed in amedical context and tests performed in a research
context and only applies to tests ordered in amedical context.
A distinction is also made between diagnostic tests and
predictive tests. In addition, the GenDG regulates genetic
screening, which would include NBS for SCD. German law
requires the establishment of an independent, interdisci-
plinary Genetic Testing Commission (GEKO), which has
been set up at the Robert Koch Institute and, amongst other
things, lays down the requirements for the performance of
genetic screening tests [49].These requirements are based on
the specific criteria for genetic screening developed byAnder-
mann et al. on the basis of theWHO screening criteria ofWil-
son and Jungner [39, 50].The GEKO has expressly stated that
results of studies performed in other countries with different
healthcare systems and different population structures can-
not necessarily be extrapolated toGermany [51]. For example,
some screening criteria are based on local conditions, which
do not obtain in Germany or at least not in all parts of the
country. Sickle cell patients cannot, in particular, be offered
state-of-the-art care everywhere in Germany. Nonmalignant
hematology has been almost entirely neglected in the training
of all groups of healthcare professionals in the past and the
hemoglobinopathies as a whole are still not seen as a problem
in Germany. However, a national strategy for prevention
and treatment of SCD is currently under development. The
Society for Pediatric Oncology and Hematology (GPOH)
has commissioned the establishment of a patient register,
reference centers, and a treatment guideline.This is important
because, if it is to make any sense, a newborn screening
program requires not only the identification of sick babies but
also a functioning infrastructure, which ensures that affected
children also receive appropriate care after the diagnosis.
This includes both medical and psychosocial care as well
as sufficient counseling resources for the patients and their
parents.
5. Conclusions
Our pilot project shows that itmakes sense, at least regionally,
to think about the introduction of some kind ofNBS program
for SCD in Germany, whatever specific form this takes.
The pilot projects necessary for this must be embarked on
now. In addition to the presumed high-prevalence regions
such as Berlin, Hamburg, the Ruhr region, or Frankfurt,
epidemiological data should also be collected from pre-
sumed low-prevalence regions (e.g., rural Bavaria and Baden-
Wu¨rttemberg).
Our data show that the organization and realization of
such pilot projects is relatively unproblematic and inexpen-
sive as samples can be collected over several months and then
analyzed together. However, we recommend that the samples
should not be older than three months at the time of analysis.
It is of fundamental importance that the Genetic Testing Act
does not apply to such pilot projects as they involve genetic
testing in the context of research.
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